Although research is advancing with great strides, the life expectancy of people with cystic fibrosis (CF) is still significantly reduced. The genetic disorder causes severe infections of the lungs associated with the increasing accumulation of mucus clogging the airways. CF is caused by mutations in the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene, resulting in the dysfunction of a chloride channel in somatic cells. Researchers have now succeeded in taking an initial step toward the development of a potential gene therapy for cystic fibrosis.

May 9, 2019
Prematurely born infants often develop a chronic lung disease known as Bronchopulmonary Dysplasia (BPD). To date, it has only been possible to diagnose the condition based on clinical symptoms and with little differentiation. DZL researchers at the Helmholtz Center in Munich and the Medical Center of the University of Munich have therefore developed a new protocol, allowing them to identify premature infants suffering from the disease by magnetic resonance imaging (MRI). Their findings have been published in Thorax.

Einen Schwerpunkt der diesjährigen 125. Jahrestagung der Deutschen Gesellschaft für Innere Medizin e.V. (DGIM) vom 4. bis 7. Mai in Wiesbaden bilden die Deutschen Zentren für Gesundheitsforschung (DZG). In wissenschaftlichen Symposien und am Gemeinschaftsstand stellen sie ihre aktuellen Forschungsergebnisse vor.

April 26, 2019

Pulmonary Arterial Hypertension (PAH) is a progressive, fatal disease of the pulmonary vasculature. Affected patients have a poor prognosis, and treatment options are limited. New scientific evidence is therefore all the more important to understand this severe disease. For their research activities in this area, Dr. Astrid Weiß and Moritz Neubauer, members of the work group “Pulmonary Pharmacotherapy” of Prof. Dr. Ralph Schermuly at Department 11 – Medicine at Giessen University (JLU), have recently been awarded the research prize of the charitable René Baumgart Foundation worth 5,000 euros in prize money.

The DZL was represented with an information desk at the 60th Congress of the German Respiratory Society (DGP), which took place in Munich from March 13–16, 2019. The Congress, themed “Pulmonology–Interdisciplinary and Interactive”, was held in cooperation with the 41st Annual Meeting of the German Society of Pediatric Pulmonology (GPP). Numerous DZL representatives gave lectures on their areas of expertise, including DGP President and DZL Board member Prof. Dr. Klaus F. Rabe. As part of the Congress, the DZL also hosted a Round Table with representatives of patient organizations and, jointly with the Lung Information Service (LIS) and the German Lung Day (Deutscher Lungentag), invited those interested to attend a patient forum.

Studying the lung microbiome requires a specialist approach to sampling, laboratory techniques and statistical analysis. In the latest ERS Monograph, Guest Editors Michael Cox, Markus Ege and Erika von Mutius bring together chapters that introduce the techniques used and discuss how respiratory sampling, 16S rRNA gene sequencing, metagenomics and the application of ecological theory can be used to examine the respiratory microbiome. The book examines the different components of the respiratory microbiome, and considers a range of contexts (from paediatrics to disease at all ages) and respiratory diseases, including asthma, COPD, interstitial lung diseases, cancer and many more.

In “The Lung Microbiome”, the Guest Editors and authors have produced a unique and comprehensive introduction to the field, which will help develop understanding about the concepts and application of this novel area of research.

Book details:
Title: The Lung Microbiome
Guest Editors: Michael J. Cox, Markus J. Ege and Erika von Mutius
Chief Editor: Robert Bals (outgoing), John R. Hurst (incoming)
Print copies available from:
Print ISBN: 978-1-84984-101-6
Online ISBN: 978-1-84984-102-3

Mit großer Besorgnis verfolgt das Deutsche Zentrum für Lungenforschung (DZL), eines der sechs Deutschen Zentren der Gesundheitsforschung, die derzeitige Diskussion zum Gesundheitsrisiko von Luftschadstoffen. Die DZL-Jahrestagung in Mannheim zum Anlass nehmend, stellt das DZL hinsichtlich seiner Position folgendes fest:

With over 10 million new tuberculosis (TB) cases and 1.6 million deaths, TB is a global health priority. Multidrug-resistant TB is of particular concern to both clinicians and national TB programmes: in 2017, there were 558 000 new rifampicin-resistant cases and 460 000 confirmed multidrug-resistant TB cases. Despite extensive investigation over the years, there is still a great deal to learn about the prevention, diagnosis and treatment of TB.

The latest ERS Monograph on Tuberculosis takes an innovative approach to the disease, beginning with a patients’ perspective chapter. The chapters that follow integrate different views on various aspects of TB, covering: epidemiology; strategies for control and elimination; clinical and laboratory diagnosis; imaging; treatment and drugs; TB in children and different patient populations; comorbidities; and clinical cases.

By bringing together global experts in the field, the book’s Guest Editors, Giovanni Battista Migliori, Graham Bothamley, Raquel Duarte and Adrian Rendon, have produced a Monograph that will not only be useful in the clinical practice of a broad range of respiratory physicians, but will be a trusted resource for many years to come.

Book details:
Title: Tuberculosis
Guest Editors: Giovanni Battista Migliori, Graham Bothamley, Raquel Duarte and Adrian Rendon
Chief Editor: Robert Bals
Print copies available from:
Print ISBN: 978-1-84984-099-6
Online ISBN: 978-1-84984-100-9

Scientists at Helmholtz Zentrum München, member of the DZL, have now reported a previously unknown pathogenic mechanism... 

Eine assoziierte Partnerschaft des Berliner Instituts für Gesundheitsforschung (BIG) mit dem Deutschen Zentrum für Lungenforschung (DZL) wurde bereits im Jahr 2017 angestoßen und im März 2018 formal vereinbart.

Die Kooperation beinhaltet unter anderem partnerschaftliche Projekte zur translationalen Lungenforschung im Bereich der Cystischen Fibrose. Weitere Kooperationen werden in den Krankheitsbereichen Pulmonale Hypertonie, Pneumonie und Akutes Lungenversagen sowie Asthma und Allergien angestrebt.

Das Berliner Institut für Gesundheitsforschung ist eine Wissenschaftseinrichtung für Translation und Präzisionsmedizin. Es wurde im März 2013 als biomedizinische Forschungseinrichtung von der Charité - Universitätsmedizin Berlin und dem Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft (MDC) in Berlin gegründet. Ziel des BIG ist es, Forschungserkenntnisse aus den Lebenswissenschaften schneller und gezielter in für Menschen nützliche medizinische Therapien, Diagnostik und Prävention zu übersetzen und klinische Beobachtungen in die Grundlagenforschung zu transferieren.

Weitere Informationen zum Berliner Institut für Gesundheitsforschung:

Upcoming Events

23.08.2019 - 24.08.2019
Summer School Pädiatrische Pneumologie 2019
07.09.2019 - 07.09.2019
12. Symposium Lunge
11.09.2019 - 13.09.2019
ETRS Annual Meeting 2019